Market Movers Today: Twitter Inc (TWTR), Tesla Inc (TSLA), InVitae Corp (NVTA), InspireMD Inc (NSPR), and More

Page 1 of 2

Twitter Inc (NYSE:TWTR) (MarketWatch)
Shares of Twitter Inc. TWTR, -10.14% sank 5.2% toward a seven-week low in midday trade Tuesday, with losses accelerating after famed short seller Andrew Left’s Citron Research said it was short the social media company’s stock. In a tweet sent at 10:44 a.m. ET, Citron said its near-term target for the stock was $25, which is about 17% below current levels. Just before the tweet went out, the stock was down about 2.4%.

Tesla Inc (NASDAQ:TSLA) (CNBC)
Tesla shares fell after the National Transportation Safety Board said it sent investigators to look into a fatal car crash last week in California, according to a post on social media. A negative analyst call from Citigroup also weighed on the stock, which has been under pressure this past one month. Citi Research on Tuesday said its analysis of the company’s Model 3 competition points to near-term risk for the stock. “We open a 90-day downside catalyst watch on Tesla shares,” the report said. Tesla shares declined 5.8 percent Tuesday to their lowest price since April of last year. The stock is down 18 percent in the last one month.

stocks, analysis, market, numbers, business, ticker, trade, money, price, investment, index, chart

bluebay/Shutterstock.com

InVitae Corp (NYSE:NVTA) (The Motley Fool)
What happened: In response to the high-growth genetic testing company announcing plans for a secondary common stock offering, shares of Invitae (NYSE:NVTA) fell 17% as of 10:40 a.m. EDT on Tuesday. So what: Invitae plans to raise $50 million through a secondary common stock. As usual, the underwriters of the deal are also being granted an option to purchase up to an additional $7.5 million worth of stock at the offering price.

InspireMD Inc (NYSEAMERICAN:NSPR) (Benzinga)
InspireMD, Inc. jumped 28 percent to $2.61 after the company disclosed that it has received regulatory approval for both CGuard EPS and MGuard Prime in Peru.




Page 1 of 2